A Non-interventional Study Investigating Semaglutide in Combination With Lifestyle-based Modifications for the Management of Obesity in Real-World Clinical Practice in Germany (WeGo Real Germany).

Launched by NOVO NORDISK A/S · Jul 15, 2025

Keywords

ClinConnect Summary

This study is looking at how well a medicine called semaglutide works to help manage obesity when used alongside lifestyle changes like diet and exercise, in everyday medical care in Germany. Semaglutide is a treatment that doctors can prescribe, and this study will observe how people do while taking it over a year in a real-world setting. Importantly, people joining the study have already decided with their doctor to start this medicine before joining, so the study won’t change their treatment.

To take part, you need to be an adult with a body weight high enough to be considered obese (a BMI of 30 or more) and have at least one related health condition like high blood pressure, pre-diabetes, sleep apnea, or heart problems—or have a BMI of 35 or higher. Participants also must have tried but not succeeded in losing weight before. The study does not include people with diabetes, pregnant or breastfeeding women, or those who have used similar treatments recently. If eligible, participants can expect to be followed for 12 months to see how semaglutide works for them in everyday life, with no changes to their usual care. This information will help doctors understand how effective and safe the medicine is outside of tightly controlled clinical trials.

Gender

ALL

Eligibility criteria

• Common inclusion criteria for Group A and Group B:
• • 1. Male or female, age above or equal to 18 years at the time signing informed consent.
• 2. Body mass index (BMI) more than or equal to (≥) 30 kilogram per meter square (kg/m\^2) with at least one of the following diagnosed obesity-related comorbidities:
• • arterial hypertension, pre-diabetes, Obstructive Sleep Apnea (OSA) or coronary heart disease, chronic heart failure, or BMI ≥35 kg/m\^2.
• • 3. History of at least one self-reported unsuccessful attempt to lose weight.
• • 4. Capable of completing informed consent.
• Additional inclusion criteria for Group A:
• • 1. The decision to initiate treatment with commercially available Wegovy has been made by the participant and the treating physician before and independently from the decision to include the participant in this study.
• • 2. Initiation of treatment is not modified in any case due to participant's participation in the study.
• Common exclusion criteria for Group A and Group B:
• • 1. Previous participation in this study (participation is defined as having given informed consent in this study)
• • 2. Treatment with an investigational drug within 30 days prior to enrolment into the study.
• • 3. Participant has had a prior serious allergic reaction to semaglutide or any of the ingredients in Wegovy.
• • 4. Women with pregnancy or breast-feeding.
• • 5. Women of childbearing potential and not using an adequate contraceptive method.
• • 6. Men and women in their pregnancy attempts.
• • 7. Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.
• • 8. History of any Glucagon-like peptide-1 (GLP-1) treatment within 180 days.
• • 9. History of type 1 or type 2 diabetes mellitus.